With the increasing number of approvals and new indications for immunotherapies for cancer, there is an ongoing need to ensure awareness and understanding of specific immune-related adverse events (irAEs) that may occur with these agents. This includes education for patients, all members of the multidisciplinary care team, and other allied clinicians on how irAEs differ from the traditional side effects of chemotherapy—in terms of both timing and manifestation—and information on how to effectively manage irAEs.
This project aims to provide needed education on the management of immune-related adverse events by compiling existing tools and resources for patient/caregiver and multidisciplinary team education and by highlighting effective care team-patient communication and practices that support proactive identification and management of irAEs.
This project is made possible by an educational donation from EMD Serono.
With increasing approvals of new immunotherapy agents and new indications for existing agents, more cancer patients are receiving immunotherapy in the community. Coordinated management of immune-related adverse events (irAEs) for these patients remains a growing challenge.
Presenter: Brianna Hoffner, MSN, ANP-BS, AOCNP, University of Colorado, School of Medicine
As the spectrum of immune-related adverse events (irAEs) expands to include less common, albeit more severe manifestations, early detection becomes increasingly vital for patient safety and treatment tolerability. If diagnosed quickly and managed properly, most irAEs are reversible. Join this webinar to gain a deeper understanding of this growing spectrum and learn how to effectively manage your patients’ irAEs using a multidisciplinary approach.
This webinar was originally presented on July 13, 2017, in conjunction with the Rocky Mountain Oncology Society (RMOS). This project is made possible by an educational donation from EMD Serono.